Evotec has significantly lowered its full-year 2026 revenue guidance by approximately 20-25% and now expects a substantial adjusted EBITDA loss, a sharp reversal from its previous positive guidance. This drastic revision indicates significant operational challenges or a deterioration in market conditions, likely leading to a strong negative market reaction for the company.
Evotec announced preliminary unaudited financial results for H1 2026 and a drastically revised full-year 2026 outlook. The company now expects FY26 revenues of €570M-€610M, down from the previous guidance of €700M-€780M, and projects an adjusted EBITDA loss of €70M-€105M, a significant downgrade from the prior positive guidance of €0M-€40M. This substantial reduction in both revenue and profitability forecasts is a major negative catalyst, indicating unforeseen operational setbacks or a significant downturn in its business prospects. Traders should anticipate a sharp negative reaction in EVO's stock price in the short term, as this news fundamentally alters the investment thesis and raises concerns about the company's future growth and financial health.